Noxopharm Ltd.
AASX:NOX0.06
AUD
+0.01
(+10.00%)
Noxopharm Ltd.
ASX:NOX
(Australian Securities Exchange)
Recent
price
0.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotechnology company that discovers and develops novel treatments for cancer and inflammation, including technologies to enhance mRNA vaccines; it operates through two proprietary platforms, Chroma for oncology and Sofra for inflammation, autoimmunity, mRNA enhancement, and oncology support. The company's core pipeline includes SOF-SKN, a first-in-class anti-inflammatory oligonucleotide in the HERACLES Phase 1 clinical trial for chronic inflammatory skin diseases; SOF-VAC, an mRNA vaccine enhancer to reduce inflammatory side effects such as fever and fatigue; SOF-XX for autoimmune diseases including lupus; CRO-67, a preclinical oncology candidate that received FDA orphan drug designation for pancreatic cancer and demonstrates up to 85% tumor cell reduction and 87% barrier cell reduction in preclinical models; and earlier assets like Veyonda (NOX66 or idronoxil) for immuno-oncology in prostate cancer and sarcomas. Noxopharm targets unmet needs in oncology, autoimmune disorders, and vaccine safety, serving patient populations with cancers such as pancreatic, prostate, glioblastoma, and leukemia, as well as inflammatory conditions; it conducts operations primarily in Australia with international collaborations. Founded in 2015 and headquartered in Sydney at Suite 71, 159 Ridgecrop Drive, Castle Hill, New South Wales, the company leverages in-house expertise and partnerships with institutions like UNSW Sydney. Recent developments include awarding a NSW Government TechVoucher grant in November 2025 for a UNSW collaboration on Sofra technology to reduce implant-related inflammation; progression of the HERACLES trial with successful completion of the second dosing cohort and advancement to higher doses; signing multiple material transfer and collaboration agreements with Australian and international academic and research institutions; securing convertible notes totaling $2.6 million with maturity extended to January 2027 pending shareholder approval at the November 2025 AGM; and presentation of promising preclinical data for Chroma platform assets at the 2025 AGM.